Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
Toward the end of trading Tuesday, the Dow traded down 1.18% to 35,204.03 while the NASDAQ fell 1.24% to 14,610.77. The S&P also fell, dropping 1.06% to 4,432.01.
Midway through trading Tuesday, the Dow traded down 0.81% to 35,336.88 while the NASDAQ fell 0.89% to 14,661.86. The S&P also fell, dropping 0.65% to 4,450.54.
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
Following the market opening Tuesday, the Dow traded down 0.67% to 35,385.44 while the NASDAQ fell 0.79% to 14,676.74. The S&P also fell, dropping 0.54% to 4,455.32.
Financial Outlook:
For the third quarter of the fiscal year 2021, monday.com currently expects:
●
Total revenue of $74 to $75 million, representing year-over-year growth of 74% to
Monday.Com (NASDAQ:MNDY) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.00) by 74 percent. The company reported quarterly sales of $70.60 million which beat the analyst